ARISAN THERAPEUTICS INC - TO CONDUCT NON-CLINICAL GOOD LABORATORY PRACTICE (GLP) IN VIVO GENOTOXICITY AND REPRODUCTIVE TOXICOLOGY AND GLP DEVELOPMENT AND REPRODUCTIVE (DART) TOXICOLOGY STUDIES.

On Nov 18, 2025, Department of Health and Human Services obligated $3,692,037 to ARISAN THERAPEUTICS INC for to conduct non-clinical good laboratory practice (glp) in vivo genotoxicity and reproductive toxicology and glp development and reproductive (dart) toxicology studies.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 7 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in CARLSBAD, CA. The contract is scheduled through Dec 31, 2026 — approximately 7 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.